VT
FOLD

Vise Technologies’s Amicus Therapeutics FOLD Stock Holding History

Vise Technologies’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$993K Hold
69,715
– – 0.02% 588
2025
Q4 		$993K Buy
69,715
+6,493
+10% +$63.8K 0.02% 592
2025
Q3 		$498K Buy
63,222
+30,533
+93% +$217K 0.02% 669
2025
Q2 		$187K Buy
+32,689
New +$211K 0.01% 1000

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Vise Technologies's FOLD Position: Q1 2026 in Review

Vise Technologies held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 69,715 shares worth $993K. The position accounts for 0.02% of the portfolio, ranked #588.

Vise Technologies first reported a position in FOLD in Q2 2025 and has held it in 4 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Vise Technologies held 69,715 shares of Amicus Therapeutics worth $993K as of Q1 2026.
  • Vise Technologies left its Amicus Therapeutics share count unchanged in Q1 2026.
  • Amicus Therapeutics made up 0.02% of Vise Technologies's portfolio in Q1 2026, its #588 holding.
  • Vise Technologies first reported a position in Amicus Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Vise Technologies's 13F filing for Q1 2026, filed 21 Apr 2026.